(Z)-11-butylidene-6,11-dihydrodibenzo[b,e]oxepine | 1449038-54-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噁庚英
• 英文名称: (Z)-11-butylidene-6,11-dihydrodibenzo[b,e]oxepine
• 英文别名: (11Z)-11-butylidene-6H-benzo[c][1]benzoxepine
• CAS: 1449038-54-3
• 化学式: C₁₈H₁₈O
• 分子量: 250.34
• InChiKey: QSCRTEUEPSNBFU-SXGWCWSVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-Bromo-2-[(2-pent-1-ynylphenoxy)methyl]benzene 在 四(三苯基膦)钯 、 sodium formate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以76%的产率得到(Z)-11-butylidene-6,11-dihydrodibenzo[b,e]oxepine
  参考文献：
  名称：

  A reductive Mizoroki–Heck approach to dibenzo[b,e]oxepine

  摘要：

  The synthesis of dibenzo[b,e]oxepine framework via palladium-mediated reductive Mizoroki-Heck reaction has been described. The procedure is simple, straightforward, and regioselective. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.06.070

文献信息

• METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP
  申请人：Rogowski Roberta L.

  公开号：US20120245222A1

  公开（公告）日：2012-09-27

  Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).

  通过给予低剂量多西平（例如1-6毫克），预防早醒，并提高睡眠效率，在睡眠周期的第7和第8个小时。
• DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS
  申请人：Somaxon Pharmaceuticals, Inc.

  公开号：US20130102658A1

  公开（公告）日：2013-04-25

  The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders

  本发明涉及使用cis-(Z)异构体或含有指定比例的cis-(Z)和trans-(E)异构体的异构混合物，多西平的代谢物，多西平的药物可接受盐和相应的前药；包含它们的组合物，用于治疗睡眠障碍。
• DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS
  申请人：Somaxon Pharmaceuticals, Inc.

  公开号：US20130096188A1

  公开（公告）日：2013-04-18

  The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders

  本发明涉及使用trans-(E)异构体或含有指定比例的trans-(E)和cis-(Z)异构体的异构混合物，doxepin的代谢物，doxepin的药学上可接受的盐和其前药，包含其的组合物，用于治疗睡眠障碍。
• LOW DOSE DOXEPIN FORMULATIONS, INCLUDING BUCCAL, SUBLINGUAL AND FASTMELT FORMULATIONS, AND USES OF THE SAME TO TREAT INSOMNIA
  申请人：Schioppi Luigi

  公开号：US20110318412A1

  公开（公告）日：2011-12-29

  The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.
• LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS
  申请人：Rogowski Roberta L.

  公开号：US20120088822A1

  公开（公告）日：2012-04-12

  Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.